137 related articles for article (PubMed ID: 30605724)
1. Ribavirin induces widespread accumulation of IMP dehydrogenase into rods/rings structures in multiple major mouse organs.
Keppeke GD; Calise SJ; Chan EKL; Andrade LEC
Antiviral Res; 2019 Feb; 162():130-135. PubMed ID: 30605724
[TBL] [Abstract][Full Text] [Related]
2. Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery.
Calise SJ; Chan EKL
Autoimmun Rev; 2020 Oct; 19(10):102643. PubMed ID: 32805424
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2018 Oct; 66(5):605-610. PubMed ID: 30220012
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
5. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
World J Gastroenterol; 2016 Feb; 22(6):1966-74. PubMed ID: 26877604
[TBL] [Abstract][Full Text] [Related]
6. Differential capacity of therapeutic drugs to induce Rods/Rings structures in vitro and in vivo and generation of anti-Rods/Rings autoantibodies.
Keppeke GD; Prado MS; Nunes E; Perazzio SF; Rodrigues SH; Ferraz ML; Chan EK; Andrade LE
Clin Immunol; 2016 Dec; 173():149-156. PubMed ID: 27746381
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.
Dammermann W; Polywka S; Dettmann I; Mindorf S; Komorowski L; Wehmeyer M; Schulze Zur Wiesch J; Stöcker W; Lüth S
Med Microbiol Immunol; 2017 Oct; 206(5):379-382. PubMed ID: 28815296
[TBL] [Abstract][Full Text] [Related]
10. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
Stinton LM; Myers RP; Coffin CS; Fritzler MJ
BMC Gastroenterol; 2013 Mar; 13():50. PubMed ID: 23506439
[TBL] [Abstract][Full Text] [Related]
11. Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.
Novembrino C; Aghemo A; Ferraris Fusarini C; Maiavacca R; Matinato C; Lunghi G; Torresani E; Ronchi M; Garlaschi MC; Ramondetta M; Colombo M
J Viral Hepat; 2014 Dec; 21(12):944-9. PubMed ID: 25040504
[TBL] [Abstract][Full Text] [Related]
12. Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.
Calise SJ; Bizzaro N; Nguyen T; Bassetti D; Porcelli B; Almi P; Barberio G; Pesce G; Satoh M; Chan EK
Auto Immun Highlights; 2016 Dec; 7(1):15. PubMed ID: 27844412
[TBL] [Abstract][Full Text] [Related]
13. Immune Response-Dependent Assembly of IMP Dehydrogenase Filaments.
Calise SJ; Abboud G; Kasahara H; Morel L; Chan EKL
Front Immunol; 2018; 9():2789. PubMed ID: 30555474
[TBL] [Abstract][Full Text] [Related]
14. Anti-rods/rings: a human model of drug-induced autoantibody generation.
Calise SJ; Keppeke GD; Andrade LE; Chan EK
Front Immunol; 2015; 6():41. PubMed ID: 25699057
[TBL] [Abstract][Full Text] [Related]
15. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.
Keppeke GD; Satoh M; Ferraz ML; Chan EK; Andrade LE
Immunol Res; 2014 Oct; 60(1):38-49. PubMed ID: 24845459
[TBL] [Abstract][Full Text] [Related]
16. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.
Markland W; McQuaid TJ; Jain J; Kwong AD
Antimicrob Agents Chemother; 2000 Apr; 44(4):859-66. PubMed ID: 10722482
[TBL] [Abstract][Full Text] [Related]
17. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.
Zhou S; Liu R; Baroudy BM; Malcolm BA; Reyes GR
Virology; 2003 Jun; 310(2):333-42. PubMed ID: 12781720
[TBL] [Abstract][Full Text] [Related]
18. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
19. Treating HCV with ribavirin analogues and ribavirin-like molecules.
Gish RG
J Antimicrob Chemother; 2006 Jan; 57(1):8-13. PubMed ID: 16293677
[TBL] [Abstract][Full Text] [Related]
20. Loukoumasomes Are Distinct Subcellular Structures from Rods and Rings and Are Structurally Associated with MAP2 and the Nuclear Envelope in Retinal Cells.
Noble JW; Hunter DV; Roskelley CD; Chan EK; Mills J
PLoS One; 2016; 11(10):e0165162. PubMed ID: 27798680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
